Navigation Links
CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
Date:12/17/2013

COPENHAGEN, Denmark; SEATTLE; STRASBOURG, France; and SAN FRANCISCO, Dec. 17, 2013 /PRNewswire/ -- CMC Biologics and OncoSynergy announced today that the two companies entered into an agreement for cell-line development, process development, analytical development and manufacturing of non-GMP material to enable early toxicology testing and cGMP material for IND enabling toxicology studies and Phase I clinical trials. This work will advance OncoSynergy's OS2966 monoclonal antibody program based on its "Targeted Synergy" approach - a transformative strategy allowing broad inhibition of multiple fundamental cancer growth mechanisms with a single drug.

(Logo: http://photos.prnewswire.com/prnh/20131217/SF34565LOGO)

(Logo: http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

"We look forward to helping advance OncoSynergy's OS2966 drug platform targeting cancers resistant to currently available therapies," said Gustavo Mahler, Global Chief Operations Officer of CMC Biologics. "This contract highlights CMC Biologics' proven and trusted platform for monoclonal antibody development and manufacturing." 

The project will be executed by CMC Biologics at its Copenhagen development and manufacturing facility. OncoSynergy EU SAS in France will lead the project.

"We are impressed with CMC Biologics' experience and technical competency in biopharmaceutical development and cGMP manufacturing," said OncoSynergy Co-Founder and CEO, Shawn Carbonell, MD, PhD. "Choosing a partner who can provide a complete solution - from expression of the sequence of interest, to providing material suitable for clinical trials - was a critical decision as we advance our lead candidate. They have also shown flexibility to accommodate our unique program needs as a virtual startup company."

About OncoSynergy
OncoSynergy is a privately-held biotechnology company based in San Francisco, California and Strasbourg, France. The mission of OncoSynergy is to radically improve health outcomes for patients by addressing unmet needs in oncology and neurofibromatosis. Its therapies are drug platforms featuring "Targeted Synergy" - multiple mechanisms of action for maximal effectiveness. OncoSynergy's lead drug, OS2966, blocks a critical path for growth and therapy resistance in cancer and is under development for the treatment of glioblastoma. OncoSynergy's therapeutic platforms have been developed at several world-class institutions including by its founders at UCSF and by Martin Karplus of Harvard University - a 2013 Nobel Prize in Chemistryawardee. To learn more, visit www.oncosynergy.com.

About CMC Biologics 
CMC Biologics is a dedicated contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes. To learn more, visit www.cmcbiologics.com.

Media Contacts:
Stacie D. Byars
CMC Biologics Global Marketing
sbyars@cmcbio.com
+1 (206) 660-2588

Robert Dunkle
OncoSynergy, Inc.
bob@oncosynergy.com
+1 (415) 978-2153


'/>"/>
SOURCE CMC Biologics; OncoSynergy
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Crescendo Biologics Raises £17.5M ($28M) in Series A Financing
2. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
3. Synthetic Biologics Webcast Conference Call Set for 9:00 a.m. EST this Morning, December 9th
4. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
5. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
6. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
7. Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety
8. Bone Biologics to Webcast, Live, at RetailInvestorConferences.com on September 12th
9. Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland
10. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
11. Oncobiologics and inVentiv Health Form Strategic Partnership around Biosimilars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
Breaking Medicine News(10 mins):